Cosmetic Peptide Retatrutide LY-3437943 A Triple Agonist for Significant Weight Loss and Obesity Control

Cosmetic Peptide Retatrutide LY-3437943 A Triple Agonist for Significant Weight Loss and Obesity Control

Product desciption:

Retatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R, while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependent insulinotropic polypeptide (GIP). In vitro, Retatrutide demonstrates similar efficacy to natural glucagon in evoking glucose production within hepatocytes. While in adipocytes, it surpasses native GIP in inducing lipolysis. The data from the trials mentioned in this manuscript indicates that Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity. Retatrutide demonstrates dosage‐dependent pharmacokinetics, featuring a favorable half‐life of nearly 6 days, thereby enabling convenient weekly administration. Additionally, GLP‐1 and GCG are known to significantly delay GE in humans, while GIP may have no impact on GE. Delayed GE reduces food consumption and therefore leads to weight reduction.

Related products:

Product Photos:

Certifications:

Company:

FAQ: